Vanegas Múnera Johanna Marcela, Ocampo Ríos Ana María, Urrego Daniela Montoya, Jiménez Quiceno Judy Natalia
Universidad de Antioquia, Escuela de Microbiología, Grupo de Microbiología Básica y Aplicada, Medellín, Colombia.
Universidad de Antioquia, Escuela de Microbiología, Grupo de Microbiología Básica y Aplicada, Medellín, Colombia.
Braz J Infect Dis. 2017 Sep-Oct;21(5):493-499. doi: 10.1016/j.bjid.2017.03.010. Epub 2017 Apr 19.
Treatment of multidrug-resistant Gram-positive infections caused by Staphylococcus aureus remains as a clinical challenge due to emergence of new resistance mechanisms. Tedizolid is a next-generation oxazolidinone, recently approved for skin and soft tissues infections. We conducted a study to determine in vitro susceptibility to vancomycin, daptomycin, linezolid and tedizolid in MRSA clinical isolates from adult patients with skin and soft tissue infections.
Methicillin-resistant S. aureus isolates were collected in three tertiary-care hospitals of Medellin, Colombia, from February 2008 to June 2010 as part of a previous study. Clinical characteristics were assessed by medical records and MIC values were determined by Epsilometer test. Genotypic analysis included spa typing, MLST, and SCCmec typing.
A total of 150 MRSA isolates were evaluated and tedizolid MIC values obtained showed higher in vitro activity than other antimicrobials, with MIC values ranging from 0.13μg/mL to 0.75μg/mL and lower values of MIC and MIC (0.38μg/mL and 0.5μg/mL) In contrast, vancomycin and linezolid had higher MIC values, which ranged from 0.5μg/mL to 2.0μg/mL and from 0.38μg/mL to 4.0μg/mL, respectively. Tedizolid MICs were 2- to 5-fold lower than those of linezolid. Clinical characteristics showed high previous antimicrobial use and hospitalization history. The majority of the strains belong to the CC8 harboring the SCCmec IVc and were associated with the spa t1610 (29.33%, n=44).
In vitro effectiveness of tedizolid was superior for isolates from skin and soft tissue infections in comparison with the other antibiotics evaluated. The above added to its less toxicity, good bioavailability, daily dose and unnecessity of dosage adjustment, make tedizolid in a promising alternative for the treatment of infections caused by MRSA.
由于新的耐药机制出现,治疗由金黄色葡萄球菌引起的多重耐药革兰氏阳性感染仍然是一项临床挑战。特地唑胺是一种新一代恶唑烷酮类药物,最近被批准用于治疗皮肤和软组织感染。我们开展了一项研究,以确定成年皮肤和软组织感染患者的耐甲氧西林金黄色葡萄球菌(MRSA)临床分离株对万古霉素、达托霉素、利奈唑胺和特地唑胺的体外敏感性。
作为之前一项研究的一部分,于2008年2月至2010年6月在哥伦比亚麦德林的三家三级护理医院收集耐甲氧西林金黄色葡萄球菌分离株。通过病历评估临床特征,并通过Epsilometer试验确定最低抑菌浓度(MIC)值。基因分型分析包括spa分型、多位点序列分型(MLST)和葡萄球菌染色体盒式Mec(SCCmec)分型。
共评估了150株MRSA分离株,所得特地唑胺MIC值显示出比其他抗菌药物更高的体外活性,MIC值范围为0.13μg/mL至0.75μg/mL,MIC50和MIC90值较低(分别为0.38μg/mL和0.5μg/mL)。相比之下,万古霉素和利奈唑胺的MIC值较高,分别为0.5μg/mL至2.0μg/mL和0.38μg/mL至4.0μg/mL。特地唑胺的MIC值比利奈唑胺低2至5倍。临床特征显示既往抗菌药物使用频率高和有住院史。大多数菌株属于携带SCCmec IVc的克隆复合体8(CC8),并与spa t1610相关(29.33%,n = 44)。
与其他评估的抗生素相比,特地唑胺对皮肤和软组织感染分离株的体外有效性更佳。上述特点加上其较低的毒性、良好的生物利用度、每日剂量以及无需调整剂量,使得特地唑胺成为治疗MRSA引起的感染的一种有前景的替代药物。